We are a clinical-stage biotechnology company developing best-in-class bromodomain and extra-terminal inhibitors (BETi) for the treatment of multiple cancers and other disorders with significant unmet medical need. Our goal is to be a leading oncology company in the field of epigenetics, translating bromodomain biology into impactful, targeted therapeutics for the benefit of patients.

Learn More

About Zenith Epigenetics

Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.

Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.



Prostate Cancer Drug Development Summit

Zenith will be presenting at the Prostate Cancer Drug Development Summit on August 19, 2021. More info can be found HERE.

"Advance the Development of an Epigenetic-based Therapy in Castration-Resistant Prostate Cancer (CRPC)"
• Explore the combination of the BET bromodomain inhibitor ZEN-3694
with enzalutamide: updated results from the Phase 2a trial
• Discover mechanisms of resistance to enzalutamide targeted
by ZEN-3694
• Examine translational data informing patient pre-selection strategy

Add This to my Calendar

Epigenetic Therapeutic Targets

Zenith will be presenting at the Epigenetic Therapeutic Targets digital event on July 15. More info can be found HERE.

"Clinical Development of The BET Bromodomain Inhibitor ZEN-3694 In Solid Tumors: Lessons Learned"
• Design of epigenetic combinatorial therapies
• Clinical activity in breast and prostate cancer patients
• Mechanisms of action: similarities and differences between the prostate
and breast cancer trials

Add This to my Calendar

Triple Negative Breast Cancer Drug Development Digital Summit 2021

On April 29, 2021, Dr. Eric Campeau will be presenting at the Triple Negative Breast Cancer Drug Development Digital Summit 2021: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations." More info can be found HERE

Add This to my Calendar

AACR Annual Meeting 2021 - Virtual

On April 10, 2021, Zenith Epigenetics will be participating at the AACR Annual Meeting 2021 - Virtual, presenting the following poster: "Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status." More info can be found HERE

Add This to my Calendar